ReviewCurrent hypertension reports2019
Personalized Medicine and the Treatment of Hypertension.
Review in Current hypertension reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Prescribing trends and time series analysis of blood pressure-lowering drugs among patients with dementia: a multinational database study.EClinicalMedicine · 2025Article
- Vision transformer-based stratification of pre/diabetic and pre/hypertensive patients from retinal photographs for 3PM applications.The EPMA journal · 2025Article
- Applications, Challenges, and Future Perspectives of Artificial Intelligence in Psychopharmacology, Psychological Disorders and Physiological Psychology: A Comprehensive Review.Journal of pharmacy & bioallied sciences · 2025Review
- Article
- Heterogeneity in response to treatment across tinnitus phenotypes.Scientific reports · 2024Article
- CURATE.AI-assisted dose titration for anti-hypertensive personalized therapy: study protocol for a multi-arm, randomized, pilot feasibility trial using CURATE.AI (CURATE.AI ADAPT trial).European heart journal. Digital health · 2024Article
- Polypill Therapy for Cardiovascular Disease Prevention and Combination Medication Therapy for Hypertension Management.Journal of clinical medicine · 2023Review
- Personalized Medicine in Kidney Disease.Journal of personalized medicine · 2023Article
- Observational
- Personalized hypertension treatment recommendations by a data-driven model.BMC medical informatics and decision making · 2023Article
- The link between immunity and hypertension in the kidney and heart.Frontiers in cardiovascular medicine · 2023Review
- Personalized antihypertensive treatment guided by pharmacogenomics in China.Cardiovascular diagnosis and therapy · 2022Article
- Clinical Network for Big Data and Personalized Health: Study Protocol and Preliminary Results.International journal of environmental research and public health · 2022Article
- Application of vascular endothelial cells in stem cell medicine.World journal of clinical cases · 2021Review
- Traditional Chinese Medicine Injections Combined With Antihypertensive Drugs for Hypertensive Nephropathy: A Network Meta-Analysis.Frontiers in pharmacology · 2021Review
- Effect of Serum Albumin Changes on Mortality in Patients with Peritoneal Dialysis: A Joint Modeling Approach and Personalized Dynamic Risk Predictions.BioMed research international · 2021Article
- Connected Health in Hypertension Management.Frontiers in cardiovascular medicine · 2019Review
- Walking and resting blood pressure: An inter-individual response difference meta-analysis of randomized controlled trials.Science progressArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
purpose of reviewThe purpose of this review is to discuss the implications of personalized medicine for the treatment of hypertension, including resistant hypertension. RECENT
findingsWe suggest a framework for the personalized treatment of hypertension based on the concept of a trade-off between simplicity and personalization. This framework is based on treatment strategies classified as low, medium, or high information burden personalization approaches. The extent to which a higher information burden is justified depends on the clinical scenario, particularly the ease with which the blood pressure can be controlled. A one-size-fits-many treatment strategy for hypertension is efficacious for most people; however, a more personalized approach could be useful in patients with subtypes of hypertension that do not respond as expected to treatment. Clinicians seeing patients with unusual hypertension phenotypes should be familiar with emerging trends in personalized treatment of hypertension.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.